Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Quantum Genomics
  6. News
  7. Summary
    ALQGC   FR0011648971

QUANTUM GENOMICS

(ALQGC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension

05/19/2021 | 12:41pm EDT

PARIS, May 19, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension and heart failure, announces the publication in Biomedicine & Pharmacotherapy of a new peer-reviewed scientific article reporting the efficacy of firibastat in combination with enalapril and hydrochlorothiazide in an experimental model of salt-sensitive hypertension (the DOCA-salt hypertensive rat).

The article, entitled "Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats" is available online on the website of the journal Biomedicine & Pharmacotherapy (Biomedicine & Pharmacotherapy - Journal - Elsevier DOI: 10.1016/j.biopha.2021.111682). The reported data demonstrate that the hypotensive effect induced in hypertensive DOCA-salt rat with a once-daily treatment consisting of firibastat associated with enalapril and hydrochlorothiazide is significantly greater than that induced by firibastat alone or by bitherapy enalapril/hydrochlorothiazide. In addition, concomitant administration of firibastat, enalapril and hydrochlorothiazide reduces plasma vasopressin levels observed in DOCA-salt rats treated with the bitherapy enalapril/hydrochlorothiazide by more than 50%, suggesting a superior diuretic effect of the tritherapy firibastat/enalapril/hydrochlorothiazide as compared to the bitherapy enalapril/hydrochlorothiazide.

“The experimental data obtained from our study of firibastat in combination with an angiotensin converting enzyme inhibitor such as enalapril and a diuretic such as hydrochlorothiazide, both widely used clinically, are particularly encouraging in the context of the FRESH and the REFRESH Phase III clinical studies,” said Fabrice Balavoine, Vice-President Research and Development of Quantum Genomics. “These data follow those already obtained from studies of firibastat as monotherapy and further reinforce our strategy of using firibastat to improve blood pressure control in hypertensive patients who are difficult to treat or resistant.”

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM) / the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).

For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contact information

Quantum Genomics 
contact@quantum-genomics.com 

 
So Bang (EUROPE) 
Financial and Media communication
quantum-genomics@so-bang.fr
 

LifeSci (USA)
 
Mike Tattory
Media Relations and Scientific communications
+1 (646) 751-4362 - mtattory@lifescipublicrelations.com
 

Primary Logo


ę GlobeNewswire 2021
All news about QUANTUM GENOMICS
07/08GLOBAL MARKETS LIVE : Microsoft, Deliveroo, Didi, Biogen, Tesla...
07/08QUANTUM GENOMICS : Quantum Genomics Enrolls First Patient in Its Pivotal Phase I..
AN
07/08Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial..
GL
07/08Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial..
CI
07/05GLOBAL MARKETS LIVE : WM Morrison, IBM, Didi...
07/05QUANTUM GENOMICS : Presentation of the Effects of QGC606 in an Experimental Mode..
AN
07/05Presentation of the Effects of QGC606 in an Experimental Model of Heart Failu..
GL
06/28QUANTUM GENOMICS : QUORUM study : Results Announcement next August 27, 2021 at 1..
AN
05/19Quantum Genomics Announces the Publication of New Scientific Article in Biome..
GL
05/19QUANTUM GENOMICS : Quantum Genomics Announces the Publication of New Scientific ..
AN
More news
Financials
Sales 2021 11,7 M 13,8 M 13,8 M
Net income 2021 -8,91 M -10,5 M -10,5 M
Net cash 2021 10,6 M 12,5 M 12,5 M
P/E ratio 2021 -8,26x
Yield 2021 -
Capitalization 114 M 135 M 135 M
EV / Sales 2021 8,87x
EV / Sales 2022 12,7x
Nbr of Employees 7
Free-Float 88,9%
Chart QUANTUM GENOMICS
Duration : Period :
Quantum Genomics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUANTUM GENOMICS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 4,25 €
Average target price 14,48 €
Spread / Average Target 240%
EPS Revisions
Managers and Directors
Jean-Philippe Milon Chief Executive Officer & Director
Benoţt Gueugnon Chief Financial Officer
Lionel SÚgard Chairman
Fabrice Balavoine Vice President-Research & Development
Bruno Besse Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
QUANTUM GENOMICS-13.22%135
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.35.73%46 608
CELLTRION, INC.-26.60%31 131
SEAGEN INC.-17.54%26 209